Recent Developments in Chimeric NSAIDs as Safer Anti‐Inflammatory Agents
Tóm tắt
Từ khóa
Tài liệu tham khảo
Singh G, 1999, Epidemiology of NSAID induced gastrointestinal complications, J Rheumatol Suppl, 56, 18
Nishio H, 2007, Involvement of prostaglandin E receptor EP2 subtype and prostacyclin IP receptor in decreased acid response in damaged stomach, J Physiol Pharmacol, 58, 407
Garner A, 1984, Gastric mucosal protective mechanisms: Roles of epithelial bicarbonate and mucus secretions, Scand J Gastroenterol, 101, 79
Kunkel SL, 1986, Prostaglandins as endogenous mediators of interleukin 1 production, J Immunol, 136, 186, 10.4049/jimmunol.136.1.186
Wertheim WA, 1993, Regulation of neutrophil‐derived IL‐8: The role of prostaglandin E2, dexamethasone, and IL‐4, J Immunol, 151, 2166, 10.4049/jimmunol.151.4.2166
Brzozowska I, 2004, Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)‐derivative of aspirin and cyclooxygenase (COX)‐2 inhibitor, J Physiol Pharmacol, 55, 773
Viappiani S, 2008, The cyclooxygenase‐inhibiting nitric oxide donator (CINOD) NCX 285 reduces inflammation and pain without causing serious gastrointestinal toxicity in animals (abstract), American College of Rheumatology Annual Scientific Meeting
Efficacy and safety study of naproxcinod in subjects with osteoarthritis of the hip. Available at:http://clinicaltrials.gov/ct2/show/record/NCT00541489?term=naproxcinod.
Efficacy and safety study of naproxcinod in subjects with osteoarthritis of the knee. Available at:http://clinicaltrials.gov/ct2/show/record/NCT00504127?term=naproxcinod.
Analgesic efficacy and safety study of naproxcinod in subjects with osteoarthritis of the knee. Available at:http://clinicaltrials.gov/ct2/show/record/NCT00542555?term=naproxcinod.
Schroeder JD, 2002, NMI‐1093: A nitricoxide‐enhanced cyclooxygenase‐2‐selective inhibitor with cardioprotective potential (abstract), 224th American Chemical Society National Meeting (Division of Medicinal Chemistry), 316
Eldik RV, 2012, Azarone (HNO) Interaction with Hemeproteins and Metalloporphyrins, 97
Manon B, 2009, Design, synthesis and evaluation of diclofenac‐antioxidant mutual prodrugs as safer NSAIDs, Indian J Chem, 48, 1279
Shalaby AM, 1998, Synthesis and comparative anti‐phlogistic potency of new proteinogenic amino acid conjugates of 2‐[2,6‐dichlorophenyl‐1‐amino]phenyl acetic acid “diclofenac, Acta Pol Pharm, 55, 211
Zhang YC, 2005, Synthesis of indomethacin conjugates with D‐glucosamine, Chin Chem Lett, 16, 179
Rasheed A, 2009, Synthesis, hydrolysis and pharmacodynamic profiles of novel prodrugs of mefenamic acid, Int J Curr Pharm Res, 1, 47
Brune K, 1993, Biliary elimination of aspirin after oral and intravenous administration in patients, Agents Actions, 44, 51
Davies NM, 1999, Sustained release and enteric coated NSAIDs: Are they really GI safe?, J Pharm Pharm Sci, 2, 5
Chen XH, 2004, Imrecoxib: A novel and selective cyclooxygenase 2 inhibitor with anti‐inflammatory effect, Acta Pharmacol Sin, 25, 927
Riendeau D, 2001, Etoricoxib (MK‐0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase‐2, J Pharmacol Exp Ther, 296, 558
Takeuchi K, 2006, Involvement of cyclooxygenase‐1, prostaglandin E2 and EP1 receptors in acid induced HCO3‐ secretion in the stomach, J Physiol Pharmacol, 57, 661
Gewirtz A, 2005, Lipoxin analogs: Novel anti‐inflammatory mediators, Curr Opin Investig Drugs, 6, 1112
LT‐NS001. Available at:http://www.logicaltx.com/product‐pipeline/lt‐ns001.php.html.
Kumar S, 2010, Synthesis, characterization and pharmacological activity of ester prodrugs of naproxen, Asian J Pharm Clin Res, 3, 208
Abdul Razzak NA, 2011, Design and synthesis of new mefenamic acid derivatives as anti‐inflammatory agents, J Al‐Nahrain Univ, 14, 38, 10.22401/JNUS.14.4.05
Verma A, 2010, Conjugation of some NSAIDs with 5‐phenyl‐2‐aminothiazole for reduced ulcerogenicity, Thai J Pharm Sci, 34, 49, 10.56808/3027-7922.2168
Uludağ MO, 2011, Stable ester and amide conjugates of some NSAIDs as analgesic and antiinflammatory compounds with improved biological activity, Turk J Chem, 35, 427
Mahdi MF, 2012, Design and synthesis of possible mutual prodrugs by coupling of NSAIDs with sulfa drugs by using glycolic acid as spacer, Pharmacie Globale (IJCP), 2, 1
NSAID prodrug platform. Available at:http://www.logicaltx.com/product‐pipeline/index.html.
Shindo K, 1995, Effect of H2‐receptor antagonists on bile acid metabolism, J Investig Med, 43, 170
Wallace JL, 2011, Proton pump inhibitors and low‐dose aspirin markedly exacerbate NSAID‐induced small intestinal injury: Link to dysbiosis?, Gastroenterology, 140, S, 10.1016/S0016-5085(11)60354-5
Why an NSAID prodrug?Available at:http://www.logicaltx.com/index.html.
DeWitt DL, 1990, The aspirin and hemebinding sites of ovine and murine prostaglandin endoperoxide synthases, J Biol Chem, 265, 5192, 10.1016/S0021-9258(19)34105-5
Clark K, 2004, Crystal structure of the lumiracoxib: Cyclooxygenase‐2 complex (abstract), 228th American Chemical Society National Meeting (Division of Biological Chemistry), 178
An innovative approach to nitric oxide donation. Available at:http://www.nicox.com/index.php/en/rd/other‐therapeutic‐areas/cardiovascular.
Developed for the relief of the signs and symptoms of osteoarthritis. Available at:http://www.nicox.com/index.php/en/rd/other‐therapeutic‐areas/naproxcinod‐osteoarthritis.
Nicox to re‐focus naproxcinod on Duchenne muscular dystrophy. Available at:http://www.drugs.com/nda/naproxcinod_140214.html.
ATB‐346 (lead drug). Available at:http://www.antibethera.com/s/ATB‐346.asp.
GI‐Safer NSAID Technology & Product Pipeline—With PLxGuard™. Available at:http://www.plxpharma.com/prodDev.htm.